BeiGene bags blockbuster deal with Anti-PD-1 Antibody Tislelizumab

BeiGene’s outlicensing deal with Novartis underscores how Chinese pharma companies are yards ahead of Indian pharma companies now. Novartis, the Swiss Big Pharma company, has agreed to pay BeiGene  $650 million upfront and up to $1.55 billion in potential regulatory and sales milestone payments plus royalties on product sales. This is in exchange…

Read More

EQRx and Equivalars: A new biotech with a potentially radical business model

Founded in 2019, EQRx has closed 2 massive rounds in under 13 months. It first raised a Series-A round of USD200m in Jan’20 as part of its launch. Then in Jan’21, it has again shaken up the pharma world with a USD500m Series-B EQRx is targeting Equivalar medicines EQRx’ stated…

Read More

USD 6.3B of VC/PE investment in lifescience firms in Jan’21

We recorded 114 venture capital / private equity (VC/PE) transactions pertaining to the global life sciences sector for January 2021, aggregating to a sum of USD 6.275B. USA recorded 64 transactions for with total investment of USD 4B. China reported investment of USD 1B over 15 VC/PE transactions. India saw…

Read More

Opponents of Farm Bills need to see Budget figures on MSP based procurement

The data shared by the Union Government as part of the Budget process for fiscal 21-22 should allay concerns of those thinking that the new farm bills spell doomsday for farmers. The activists fronting for the farmers are claiming the government will do away with Minimum Support Price (MSP), stop…

Read More